Abstract:Urocortin-2 (UCN2) is cardioprotective in ischemia/reperfusion injury (I/R) through short-lived activation of ERK1/2. Key factors involved in I/R, e.g. apoptosis, mitochondrial damage, p38 kinase, and Bcl-2 family, have not been well-investigated in UCN2-induced cardioprotection. We assessed the role of p38-MAPK in anti-apoptotic Bcl-2 signaling and mitochondrial stabilization as a putative mechanisms in UCN2-induced cardioprotection. Isolated hearts from adult Sprague-Dawley rats and cultured H9c2 cells were … Show more
“…Akt was not affected by any drug administered (MCT/hUcn-2), as previously reported in. 51 Increased STAT3 and GSK3b phosphorylation and reduced Bax/Bcl-2 ratio in MU rats match what has been previously described in vitro, 52,53 demonstrating the cardioprotective Ucn-2 proprieties.…”
Ucn-2 levels are altered in human and experimental PAH. hUcn-2 treatment attenuates PAH and RV dysfunction in MCT-induced PH, has direct anti-remodelling effects on the pressure-overloaded RV, and improves pulmonary vascular function.
“…Akt was not affected by any drug administered (MCT/hUcn-2), as previously reported in. 51 Increased STAT3 and GSK3b phosphorylation and reduced Bax/Bcl-2 ratio in MU rats match what has been previously described in vitro, 52,53 demonstrating the cardioprotective Ucn-2 proprieties.…”
Ucn-2 levels are altered in human and experimental PAH. hUcn-2 treatment attenuates PAH and RV dysfunction in MCT-induced PH, has direct anti-remodelling effects on the pressure-overloaded RV, and improves pulmonary vascular function.
“…The opening of the mitochondrial permeability transition pore (MPTP) in reperfusion injury is recognized as being crucial in myocyte cell death [58]. Ucn-2 is cardioprotective in I/R in association with decreased phosphorylation of p38 together with increased ERK1/2 activation and increased Bcl-2 family member pro-survival signaling [59] (Fig. 3).…”
Section: Ucn-2-crh-r2 Signaling In Myocardial Ischemiamentioning
“…Encouragingly, after IR injury, IL-33 treatment significantly reduced the myocardial infarct size and the expression of biomarkers of myocardial damage including cardiac troponin I (cTnI), lactate dehydrogenase (LDH), and creatine kinase (CK); markedly inhibited I/R-induced apoptosis of myocardiocytes; and reduced the inflammatory response in myocardial I/R by decreasing the expression of the proinflammatory cytokine HMGB1, which plays a deleterious role in myocardial IR [75,85,86] and upregulates the expression of classic 1 proinflammatory cytokines (tumor necrosis factor-α (TNF-α) and IL-6) [75,84]. As further confirmation of these effects of IL-33 and ST2L binding, the anti-inflammatory and antiapoptotic effects of IL-33 were found to be suppressed in ST2(-/-) mice [83] or upon inhibition of the p38 MAPK signaling pathway, which is a known IL-33/ST2 downstream signaling pathway in IR injury [84,87]. Based on evidence that IL-33 activates the p38 MAPK signaling pathway to inhibit TNF-α and IL-6 expression in the myocardium [88], that in the context of liver IR injury, IL-33 upregulates the expression of antiapoptotic proteins by activating the p38 MAPK signaling pathway [78], and that the p38 MAPK signaling pathway is involved in HMGB1 release [89,90], it can be presumed that in heart IR injury, IL-33 activates p38 MAPK signaling to inhibit the release of HMGB1 and then leads to downstream anti-inflammatory effects including the decreased production of cytokines such as TNF-α and IL-6.…”
Section: Il-33 and Allograft Ischemia-reperfusion (Ir) Injurymentioning
Interleukin-33 (IL-33) is a member of the IL-1 family of proteins that are produced by a variety of cell types in multiple tissues. Under conditions of cell injury or death, IL-33 is passively released from the nucleus and acts as an "alarmin" upon binding to its specific receptor ST2, which leads to proinflammatory or anti-inflammatory effects depending on the pathological environment. To date, numerous studies have investigated the roles of IL-33 in human and murine models of diseases of the nervous system, digestive system, pulmonary system, as well as other organs and systems, including solid organ transplantation. With graft rejection and ischemia-reperfusion injury being the most common causes of grafted organ failure or dysfunction, researchers have begun to investigate the role of IL-33 in the immune-related mechanisms of graft tolerance and rejection using heart transplantation models. In the present review, we summarize the identified roles of IL-33 as well as the corresponding mechanisms by which IL-33 acts within the progression of graft rejection after heart transplantation in animal models.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.